DEF 14A: PAVmed Inc. Announces Annual Stockholder Meeting to Elect Directors and Ratify Accountant

PAVmed Inc. will hold its annual stockholder meeting on June 20, 2024, to elect two Class B directors and ratify the appointment of Marcum LLP as its independent accounting firm.

Summary

• PAVmed Inc. is holding its annual meeting of stockholders on June 20, 2024, at 10:00 a.m. Eastern time, as a virtual meeting.
• The meeting will address the election of two Class B directors and the ratification of Marcum LLP as the company's independent registered certified public accounting firm for the year ending December 31, 2024.
• The Board recommends voting FOR the election of the management nominees and FOR the ratification of the accountant.
• The record date for determining stockholders entitled to vote is April 22, 2024.
• As of the record date, 9,431,721 shares of common stock were outstanding.
• The Board is divided into three classes, Class A, Class B and Class C.
• Currently, there are two directors in Class B, James L. Cox, M.D. and Debra J. White, whose terms expire at the Annual Meeting, three directors in Class C, Lishan Aklog, M.D., Michael J. Glennon and Joan B. Harvey, whose terms expire at the 2025 annual meeting of stockholders, and two directors in Class A, Ronald M. Sparks and Timothy Baxter, whose terms expire at the 2026 annual meeting of stockholders.
• The Board is nominating James L. Cox, M.D. and Debra J. White, each a current Class B director, for re-election as the Class B directors.
• Marcum LLP has served as the Company's independent registered public accounting firm since the fiscal year ended December 31, 2019.
• Audit fees for 2023 were $864,000, compared to $723,000 in 2022.
• The company's common stock is listed on the Capital Market of The Nasdaq Stock Market LLC (Nasdaq).
• The Board met eight times and acted by written consent three times during the fiscal year ended December 31, 2023.
• The Company intends to hold its 2025 annual meeting of stockholders on June 18, 2025.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The information is presented in a factual and straightforward manner, with no overt positive or negative sentiment expressed. The board's recommendations are clearly stated, but the overall tone is professional and objective.

Positives

• The Board is recommending experienced individuals for re-election as Class B directors.
• The Board is recommending the ratification of an accounting firm that has served the company since 2019.
• The company has a code of ethics that applies to all of its executive officers, directors and employees.
• The company has an insider trading policy that prohibits short sales, transactions in derivatives, and hedging of the company's securities by its directors, executive officers, employees and consultants and prohibits pledging of the company's securities by them.

Negatives

• The company is bearing the cost of the proxy solicitation.
• The company is not paying discretionary bonuses to executive officers as part of efforts to preserve cash.

Risks

• Certain officers have fiduciary obligations to other companies engaged in medical device business activities, which could lead to conflicts of interest.
• Lucid may produce devices that compete directly or indirectly with the Company's products.
• The company's management services agreement with Lucid could be terminated at any time by Lucid's board of directors.
• The company's reliance on Lucid for revenue could be impacted if Lucid's board of directors determines it would be in Lucid's best interest to engage a dedicated management team.

Future Outlook

The Company intends to hold its 2025 annual meeting of stockholders on June 18, 2025.

Management Comments

• The Board recommends that you vote FOR the election of the management nominees in the Director Election Proposal.
• The Board recommends that you vote FOR the Accountant Ratification Proposal.

Industry Context

This announcement is a routine part of corporate governance for publicly traded companies, ensuring shareholders have a voice in key decisions such as electing directors and ratifying the appointment of auditors.

Comparison to Industry Standards

• The director compensation structure, including annual retainers and equity grants, is generally in line with industry standards for companies of similar size and stage.
• The audit fee paid to Marcum LLP is comparable to fees paid by other small-cap medical device companies for similar services.
• The company's corporate governance practices, such as having a majority of independent directors and standing audit, compensation, and nominating committees, align with Nasdaq listing requirements and best practices.

Related Party Transactions

• Lucid paid or accrued a total of approximately $9.0 million and $5.6 million in the years ended December 31, 2023 and 2022, respectively under the management services agreement.
• Lucid paid or accrued a total of approximately $1.8 million and $10.2 million in the year ended December 31, 2023 and 2022, respectively, under the PBERA.

Stakeholder Impact

• Shareholders have the opportunity to vote on key decisions regarding the company's governance and direction.
• Employees are affected by the company's compensation policies and benefit plans.
• The company's performance and strategic decisions impact its customers, suppliers, and creditors.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its annual meeting on June 20, 2024.
• The company intends to hold its 2025 annual meeting of stockholders on June 18, 2025.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Director Election, Accountant Ratification, Board of Directors, PAVmed, Lucid Diagnostics, Corporate Governance